Lung Cancer Screening, Lung Nodule, and Lung Cancer Biorepository

Date Added
April 24th, 2025
PRO Number
Pro00143404
Researcher
Gerard Silvestri

List of Studies


Keywords
Cancer, Lung
Summary

This study will enroll patients and collect blood samples from those who are either in lung cancer screening, have a lung nodule that is suspicious for malignancy, a newly diagnosed cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

Institution
MUSC
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Date Added
April 2nd, 2025
PRO Number
Pro00142948
Researcher
Theodore Gourdin

List of Studies


Keywords
Cancer, Cancer/Genitourinary, Drug Studies, Men's Health
Summary

This study is for patients that have been diagnosed with metastatic castration-resistant prostate cancer. The study is testing an investigational drug called JANX007. Investigational means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of the study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX007 when administered as a single agent. The drug is given to participants by IV infusion. Participants in this study can expect to be in this study until disease progression or unacceptable toxicity.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Date Added
March 25th, 2025
PRO Number
Pro00136956
Researcher
Abirami Sivapiragasam

List of Studies

Keywords
Cancer, Cancer/Breast, Drug Studies, Women's Health
Summary

The study is for patient that are receiving camizestrant as a treatment. The main purpose of study is to change the dosage of camizestrant from 150mg to 75mg. This change was prompted by updated, emerging data from ongoing studies showing
no difference in efficacy between the 75 mg and 150 mg doses. Subject can expect to be in this study for up to 24 months.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Chester Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Florence Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Lancaster Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Marion Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Kershaw Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Columbia Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu



-- OR --